Yang H - Search Results

1

Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.

Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE 4th. Yang H, et al. Among authors: yang c. Antivir Ther. 2017;22(5):413-420. doi: 10.3851/IMP3132. Epub 2017 Jan 20. Antivir Ther. 2017. PMID: 28106531

2

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.

Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S. Yang H, et al. Hepatology. 2002 Aug;36(2):464-73. doi: 10.1053/jhep.2002.34740. Hepatology. 2002. PMID: 12143057 Clinical Trial.

3

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

Westland CE, Yang H, Delaney WE 4th, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brosgart CL, Xiong S; 437 and 438 Study Teams. Westland CE, et al. Among authors: yang h. Hepatology. 2003 Jul;38(1):96-103. doi: 10.1053/jhep.2003.50288. Hepatology. 2003. PMID: 12829991 Clinical Trial.

4

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1.

Westland C, Delaney W 4th, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Westland C, et al. Among authors: yang h. Gastroenterology. 2003 Jul;125(1):107-16. doi: 10.1016/s0016-5085(03)00700-5. Gastroenterology. 2003. PMID: 12851876 Clinical Trial.

5

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Angus P, et al. Among authors: yang h. Gastroenterology. 2003 Aug;125(2):292-7. doi: 10.1016/s0016-5085(03)00939-9. Gastroenterology. 2003. PMID: 12891527

6

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

Delaney WE 4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S. Delaney WE 4th, et al. Among authors: yang h. J Virol. 2003 Nov;77(21):11833-41. doi: 10.1128/jvi.77.21.11833-11841.2003. J Virol. 2003. PMID: 14557667 Free PMC article.

7

In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.

Yang H, Westland C, Xiong S, Delaney WE 4th. Yang H, et al. Antiviral Res. 2004 Jan;61(1):27-36. doi: 10.1016/j.antiviral.2003.07.003. Antiviral Res. 2004. PMID: 14670591

8

Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.

Delaney WE 4th, Yang H, Miller MD, Gibbs CS, Xiong S. Delaney WE 4th, et al. Among authors: yang h. Antimicrob Agents Chemother. 2004 Oct;48(10):3702-10. doi: 10.1128/AAC.48.10.3702-3710.2004. Antimicrob Agents Chemother. 2004. PMID: 15388423 Free PMC article.

9

Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.

Westland CE, Yang H, Delaney WE 4th, Wulfsohn M, Lama N, Gibbs CS, Miller MD, Fry J, Brosgart CL, Schiff ER, Xiong S. Westland CE, et al. Among authors: yang h. J Viral Hepat. 2005 Jan;12(1):67-73. doi: 10.1111/j.1365-2893.2005.00578.x. J Viral Hepat. 2005. PMID: 15655050

10

Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.

Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th. Yang H, et al. Antivir Ther. 2005;10(5):625-33. Antivir Ther. 2005. PMID: 16152756

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61,334 results

Search Page

Filters